Atypical antipsychotics: Considerations for medicaid coverage

American Journal of Managed Care

Volumn 11, Issue SUPPL. 8, 2005, Pages

  Surles, Richard C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; BIPOLAR DISORDER; BUDGET; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE POLICY; HUMAN; MEDICAID; MONEY; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; UNITED STATES; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COST CONTROL; HUMANS; MEDICAID; PATIENT COMPLIANCE; TREATMENT OUTCOME; UNITED STATES;

EID: 25444469935     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Koyanagi C, Forquer S, Alfano E. Medicaid policies to contain psychiatric drug costs. Health Aff (Millwood). 2005;24:536-544.
2. Soumerai S. Unintended outcomes of Medicaid drug cost-containment policies on the chronic mentally ill. J Clin Psychiatry. 2003;64(suppl 17):19-22.
3. Ray WA, Daugherty JR, Meador KG. Effect of a mental health "carve-out" program on the continuity of antipsychotic therapy. N Engl J Med. 2003;348:1885-1894.
4. Muller N. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry. 2004;37(suppl 2):S141-S147.
5. Teutsch SM, Berger ML, Weinstein MC. Comparative effectiveness: asking the right questions, choosing the right method. Health Aff (Millwood). 2005;24:128-132.
6. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28(suppl 1):83-96.
7. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004;27:596-601.
8. Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Prac. 2005;59:485-495.
9. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004;65:1377-1388.
10. West JC, Wilk JE, Olfson M, et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv. 2005;56: 283-291.
11. Parks J, Surles R. Using best practices to manage psychiatric medications under Medicaid. Psychiatr Serv. 2004;55:1227-1229.
12. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886-891.
13. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-699.
14. Ware NC, Tugenberg T, Dickey B. Practitioner relationships and quality of care for low-income persons with serious mental illness. Psychiatr Serv. 2004; 55:555-559.
15. Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health. 2004;7:22-35.
16. Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol. 2005; 20:105-112.
17. Hamann J, Leucht S, Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry. 2003;36:18-26.
18. Tunis SL, Ascher-Svanum H, Stensland M, et al. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individualized service costs. Pharmacoeconomics. 2004;22:1-8.
19. Mauskopf J, Muroff M, Gibson PJ, et al. Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophr Bull. 2002;28:619-635.
20. Mauskopf JA, David K, Grainger DL, et al. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry. 1999;60 (suppl 19):14-19.
21. American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-932.
22. American Heart Association. Heart Disease and Stroke Statistics-2005 Update. Dallas, TX: American Heart Association, 2005.
23. Kleinman L, Lowin A, Flood E, et al. Costs of bipolar disorder. Pharmacoeconomics. 2003;21:601-622.
24. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv. 1999; 50:1303-1308.
25. Parece A, Wu E, Birnbaum H, et al. Comorbidities and costs associated with bipolar disorder (abstract). American Public Health Association 132nd Annual Meeting, November 6-10, 2004, Washington, DC.
26. Wu E, Birnbaum H, Greenberg P, et al. Drug treatment patterns and associated costs in bipolar disorder (abstract). American Public Health Association 132nd Annual Meeting, November 6-10, 2004, Washington, DC.